31.08.2012 - In a deal worth up to US$1.1bn Janssen Biotech Inc has licensed the human monoclonal antibody daratumumab from Danish Genmab A/S.
Janssen will pay US$55m up front to gain an exclusive worldwide license to develop and commercialise the patented fully human monoclonal antibody daratumumab and a backup CD38 antibody. On top of that, its parent Johnson & Johnson will invest additional US$80m in the Danish firm. After the issue of the new shares, the Horsham-based US company will own 10.7% of Genmab's share capital, the company said. The total potential agreement value including upfront payment, equity investment and milestones is in excess of US$1.1bn. Genmab could also be entitled to tiered double digit royalties.
The human monoclonal antibody daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. The monoclonal antibody is currently in development for the rare cancer multiple myeloma and may have potential in other cancer indications such as acute myeloid leukemia.
“Much had been anticipated from a licensing deal for daratumumab and we believe this deal has more than met the expectation,” Nomura Code analyst Samir Devani said in a note to investors. The deal led Genmab cut its full-year operating loss forecast between US$24m and US$32m (DKK140m to DKK190m) from US$34m to US$42m (DKK200m to DKK250m) and to raise its guidance for 2012 revenue to US$73m to US$78m (DKK435m to DKK460m) from US$63m to US$67m (DKK375m to DKK400m).
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more